Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Baxter International (NY: BAX )

31.80 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Baxter International

< Previous 1 2 3 4 5 6 7 Next >
Unveiling 5 Analyst Insights On Baxter Intl
Via Benzinga
3 Dividend Growth Stocks For Long-Term Returns
One way to measure the quality of a dividend stock is by its dividend history. Stocks with established histories of dividend growth may be likely to continue growing their dividends moving forward.... 
Via Talk Markets
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Fresenius SE's Future With Dialysis Company Unclear, Investors Seek Answers
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite holding a 32% stake, challenges like high dialysis patient mortality and... 
Via Benzinga
(BAX) - Analyzing Baxter Intl's Short Interest
Via Benzinga
A Glimpse Into The Expert Outlook On Baxter Intl Through 4 Analysts
Via Benzinga
3 Dividend Stocks For 10%+ Annual Returns
Buying undervalued dividend stocks with growth potential could lead to above-average returns. 
Via Talk Markets
Assessing Baxter Intl: Insights From 4 Financial Analysts
Via Benzinga
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Why Is Nuvo Group (NUVO) Stock Up 200% Today?
Although prenatal care specialist Nuvo Group saw its shares soar on Monday, NUVO stock faces skepticism over its SPAC merger. 
Via InvestorPlace
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses. 
Via InvestorPlace
Why Is Medical Device Maker Baxter Stock Trading Lower On Thursday?
Baxter reports Q1 adjusted EPS at $0.65, up 10% Y/Y, surpassing expectations. Sales hit $3.59 billion, with 2% growth on a reported basis. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BAX Stock Earnings: Baxter Intl Beats EPS, Beats Revenue for Q1 2024
BAX stock results show that Baxter Intl beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Earnings Outlook For Baxter Intl
Via Benzinga
Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System
FDA clears Baxter's Novum IQ LVP & SYR infusion pumps with Dose IQ Safety Software, streamlining training & reducing cognitive burden. Explore enhanced safety features & EMR interoperability. 
Via Benzinga
Exposures Product Safety
Becton, Dickinson And Co. Dividend Stock Analysis
Becton, Dickinson, and Co. provides a wide range of medical devices and diagnostic products used in hospitals, doctors' offices, research labs, and other settings. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
Novo Nordisk's FLOW trial reveals a 24% reduction in kidney disease progression, cardiovascular events, and death with semaglutide 1.0 mg compared to placebo. Impact on dialysis stocks 
Via Benzinga
Stock Market Commentary: “Volumes Are The Name Of The Game…”
Short, intermediate, and long term outlook on the market. Plus, a deep dive into our thesis on Cooper Standard 
Via Talk Markets
Barclays Maintains Overweight Rating for Baxter Intl: Here's What You Need To Know
Via Benzinga
Baxter Says 2023 Performance Reflects Strategic Initiatives With New Operating Model Without BioPharma Solutions Unit
Baxter's Q4 2023 results: $3.89 billion revenue, surpassing consensus, 4% Y/Y growth. Strong sales in Medical Products, Therapies, Kidney Care, and Pharmaceuticals segments. 
Via Benzinga
Top Picks 2024: Baxter International
Baxter International (BAX) has four divisions: Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals, and Kidney Care. The stock aggressively sold off ~65% 
Via Talk Markets
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records. 
Via Talk Markets
3 Of Our Favorite Dividend Stocks For The New Year
The S&P 500 Index appears to be wrapping up a strong year, registering a year-to-date total return of 22.2%. The good news is that there are still undervalued stocks with strong dividends to choose... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Don't Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Morgan Stanley Maintains Equal-Weight Rating for Baxter Intl: Here's What You Need To Know
Via Benzinga
Most Active Equity Options For Midday - Monday, Nov. 13
Here are the most active equity options for midday. 
Via Talk Markets
Why Is Dialysis Device And Kidney Care Provider Baxter Stock Trading Higher Today?
Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.71 billion, which beat the consensus of $3.69 billion, up 3% Y/Y on a reported basis and  
Via Benzinga
Most Active Equity Options For Midday - Wednesday, Oct. 12
Here are the most active equity options for midday. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.